cat no | io1008
A rapidly maturing, consistent and scalable isogenic system to study frontotemporal dementia (FTD).
ioGlutamatergic Neurons MAPT P301S/P301S are opti-ox precision reprogrammed glutamatergic neurons containing a genetically engineered homozygous P301S mutation in the MAPT gene encoding the tau protein.
The disease model cells show a FTD disease-related phenotype, indicated by hyperphosphorylation of tau compared to the isogenic control.
These cells are part of a range that includes a heterozygous MAPT P301S mutation, a heterozygous MAPT N279K mutation and a homozygous MAPT N279K mutation. When paired with the genetically matched (isogenic) control, wild type ioGlutamatergic Neurons, these disease model cells offer a physiologically relevant model to investigate the impact of mutant tau protein on disease progression.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Disease-related phenotype
High content ICC image analysis shows hyperphosphorylation of tau compared to the wild-type control.
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to directly investigate the impact of mutant tau protein on disease.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Hyperphosphorylation of tau observed in the disease model cells compared to the isogenic control
ioGlutamatergic Neurons MAPT P301S/P301S express neuron-specific markers comparably to the isogenic control
ioGlutamatergic Neurons MAPT P301S/P301S form structural neuronal networks by day 11
ioGlutamatergic Neurons MAPT P301S/P301S demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming
Disease-related MAPT is expressed in ioGlutamatergic Neurons MAPT P301S/P301S following deterministic programming
Do more with every vial
bit.bio
V11
bit.bio
2024
Professor Deepak Srivastava
Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders
King’s College London
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Further your disease research by pairing our wild type cells with isogenic disease models.